Learn about the latest launch news of vanzacato/tizacaftor/deuterated ivacaftor compound tablets in one article

Vanzacaftor/tezacaftor/deuterated ivacaftor combination tablets (vanzacaftor, tezacaftor and deutivacaftor) is a new targeted therapy drug that has just been approved by the U.S. FDA on December 12, 2024, on December 20, 2024, bringing new hope to patients with cystic fibrosis. This triple combination CFTR modulator is mainly suitable for cystic fibrosis patients 6 years old and above who carry at least one F508del mutation or other CFTR gene-reactive mutations. For patients with unknown genotypes, they need to confirm the presence of relevant mutations through FDA-approved CF mutation testing before use. This precision medicine requirement ensures that the drug can exert the best effect on a specific patient group. It is worth noting that this drug has not yet received marketing approval from the China National Medical Products Administration, and domestic patients must obtain it through formal cross-border medical channels if needed.

From the perspective of its mechanism of action, Vanzacato/Tizacaftor/Deuterated ivacaftor compound tablets demonstrates an innovative triple synergistic effect. Vanzacator and tizaccatol respectively act on different sites of the CFTR protein, jointly promoting the transport of the defective protein to the cell surface, and solving the key pathological link of cystic fibrosis patients' CFTR protein transport disorder. Deuterated ivacaftor further enhances the functional activity of these proteins on the cell surface, forming a complete closed therapeutic loop. This multi-target synergy enables more functional CFTR proteins to be correctly positioned and function, thereby significantly improving the patient's chloride transport function. Clinical evaluation shows that this mechanism can be objectively verified through laboratory testing and sweat chloride ion concentration measurement, providing a reliable basis for efficacy judgment.

Regarding drug prices, due to the fact that vanzacato/tizacaftor/deuterated ivacaftor compound tablets has just obtained the FDAIt was approved shortly and no official pricing information has been released yet. As an innovative targeted drug, its price is expected to be at a high level, which is consistent with the high research and development costs and relatively limited indications for this type of drug. For domestic patients, in addition to considering the cost of the drug itself, they also need to pay attention to the additional cost of cross-border acquisition and the cost of related medical consultation services. It is recommended that patients in need obtain the latest price information and purchasing channels through formal medical consultation institutions, and also pay close attention to the registration progress of the drug in China, with a view to achieving localization and accessibility as soon as possible.

In terms of clinical efficacy, Vanzacato/Tizacaftor/Deuterated ivacaftor compound tablets’s triple mechanism of action shows significant advantages. Compared with traditional single or dual CFTR modulators, this innovative combination can more comprehensively correct the functional defects of CFTR protein, thereby leading to better clinical symptom improvement. Early clinical research data shows that the drug can significantly improve patients' lung function indicators and quality of life scores, and reduce the frequency of acute exacerbations. Especially for patients carrying the F508del mutation, this targeted therapy has shown encouraging results. As the drug is widely used in clinical practice, its long-term efficacy and safety data will be further enriched, providing more cystic fibrosis patients with precise treatment options.

Reference link:https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218730s000lbl.pdf